ZyVersa Therapeutics Inc. Cash Flow-to-Debt Ratio
ZyVersa Therapeutics Inc. cash flow-to-debt ratio. ZyVersa Therapeutics Inc. (ZVSA) has a Cash Flow-to-Debt Ratio of -110.21x as of September 2025, meaning its operating cash flow of $-1.41 Billion could theoretically repay -110% of its total liabilities ($12.77 Million) in one year. See ZyVersa Therapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ZyVersa Therapeutics Inc. (2020–2024)
Cash flow-to-debt ratio of ZyVersa Therapeutics Inc. from 2020 to 2024. Historical debt coverage capacity for ZyVersa Therapeutics Inc. across 5 annual periods. Also explore ZyVersa Therapeutics Inc. (ZVSA) equity growth momentum to track the company's year-over-year net asset growth rate.
ZyVersa Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2020–2024)
ZyVersa Therapeutics Inc. cash flow-to-debt ratio by year from 2020 to 2024. Year-by-year debt coverage analysis for ZyVersa Therapeutics Inc.. For the full cash flow conversion analysis, see ZyVersa Therapeutics Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.63x | $-7.56 Million | $12.08 Million | ▲ +20.8% |
| 2023 | -0.79x | $-8.72 Million | $11.04 Million | ▼ -199.1% |
| 2022 | -0.26x | $-4.89 Million | $18.51 Million | ▲ +29.1% |
| 2021 | -0.37x | $-5.08 Million | $13.63 Million | ▲ +32.6% |
| 2020 | -0.55x | $-5.11 Million | $9.24 Million | — |